Cascade Technologies Corp. announced this past weekend that Dr. Daniel L. Farkas, Chairman and CEO of Spectral Molecular Imaging (SMI), Cascade Technologies Corp.’s wholly-owned subsidiary, delivered a lecture at a major international congress in Rio de Janeiro, Brazil on September 23, 2010.
At the International Microscopy Congress, Dr. Farkas lectured–by special invitation–in a session entitled Instrumentation and Techniques in Advanced Optical Microscopy. The congress brings together a worldwide group of several hundred scientists. It focuses on optical imaging at the interdisciplinary frontiers of nanotechnology, medicine, life sciences, energy conversion and environmental protection for improved human outcomes.
“It is very important for a young company such as ours,” said Dr. Farkas, “to participate in the worldwide dialogue of dedicated researchers who are seeking to develop new and improved ways to image disease for better diagnosis and treatment. Major international conferences such as these,” he explained, “are the best venue to learn about recent developments, and at the same time communicate our ideas and advances to a community that presents great collaborative opportunities for us.”
Dr. Farkas has entitled his talk Translational Microscopy: High resolution optical imaging for the clinic. This is to reflect the translational (bench to bedside) emphasis of the material to be covered, based on results from his group’s research. This work constitutes the basis for all SMI products, and reflects SMI’s philosophy of applying advanced biophotonic technologies for addressing unmet needs in the clinical realm.
Dr. Farkas has been an active voice in international meetings through the years. He has presented approximately 200 invited and plenary talks, and has organized and chaired 25 international conferences, mostly in biomedical optics. These talks, and the invitations to present them, reflect the diversity and interdisciplinary nature of the applications enabled by the ground-breaking optical bioimaging that constitutes the core of SMI’s efforts, and the widespread interest, both scientific and clinical, that they elicit.
Headquartered in Beverly Hills, California, Spectral Molecular Imaging, Inc., a wholly-owned subsidiary of Cascade Technologies Corp, is a development-stage medical imaging device company. They are applying their proprietary hyperspectral-optical imaging technology—originally developed for satellite reconnaissance—to advance the early and accurate diagnoses of cancer and precancerous conditions. SMI is developing non-invasive, high-resolution optical imaging systems using their patented technology and other proprietary know-how for improved clinical diagnostics, primarily in the field of cancer pathology, by identification and analysis of certain molecular, cellular, and tissue features via hyperspectral-imaging approaches.
For more information visit: www.spectralmi.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment